Onward Ho: Biocon Signals Glargine Build Up, US Biosimilars Pricing ‘Sanity’

Also Addresses Insulin Aspart CRL From FDA On Rival To NovoLog

Biocon anticipates significant US uptake of its Viatris-partnered interchangeable insulin glargine biosimilar on the back of commercial arrangements in place and expects to "move the market" in 2022. All eyes are also on the trajectory of biosimilar insulin aspart, which received a CRL from the US FDA.

accelerate
Glargine Opportunity Builds Up For Biocon • Source: Alamy

Supplies of Biocon’s partnered interchangeable insulin glargine biosimilar, Semglee, buoyed earnings momentum for the Indian firm’s biosimilars business in the fiscal third quarter, with “significant uptake” in store in view of several commercial arrangements already in place in the US.

Biocon Biologics’ deputy CEO Shreehas Tambe highlighted recent gains made by partner Viatris for the product, which received preferred...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business